Potential efficacy of interleukin-1 beta inhibition in lung cancer
Mené sur 10 061 patients atteints d'une athérosclérose et ayant des antécédents d'infarctus du myocarde, cet essai randomisé évalue les effets du canakinumab, un inhibiteur de l'interleukine 1 bêta, sur le risque de développer un cancer du poumon (durée médiane de suivi : 3,7 ans ; nombre de décès par cancer : 196)
Over the past two decades, a wealth of experimental and clinical data have intimately linked dysregulated production of the potent proinflammatory cytokine interleukin 1
β with several chronic inflammatory and autoimmune diseases, of which the most evidence is available for rheumatoid arthritis and cardiovascular disease (eg, atherosclerosis).1
–3 Notably, these disease associations have provided the impetus to develop clinical grade inhibitors against interleukin 1
β or its receptor, with the intereukin-1-receptor antagonist anakinra being the first such inhibitor approved for clinical use (in 2001).
The Lancet , commentaire, 2016